{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:42:30Z","timestamp":1791474150271,"version":"4.3.4"},"reference-count":235,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gadolinium-based contrast agents (GBCAs) have transformed magnetic resonance imaging (MRI) by facilitating the use of contrast-enhanced MRI to allow vital clinical diagnosis in a plethora of disease that would otherwise remain undetected. Although over 500 million doses have been administered worldwide, scientific research has documented the retention of gadolinium in tissues, long after exposure, and the discovery of a GBCA-associated disease termed nephrogenic systemic fibrosis, found in patients with impaired renal function. An understanding of the pharmacokinetics in humans and animals alike are pivotal to the understanding of the distribution and excretion of gadolinium and GBCAs, and ultimately their potential retention. This has been well studied in humans and more so in animals, and recently there has been a particular focus on potential toxicities associated with multiple GBCA administration. The purpose of this review is to highlight what is currently known in the literature regarding the pharmacokinetics of gadolinium in humans and animals, and any toxicity associated with GBCA use.<\/jats:p>","DOI":"10.1007\/s00204-021-03189-8","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:03:13Z","timestamp":1641600193000},"page":"403-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8119-7981","authenticated-orcid":false,"given":"Julie","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Siebenhandl-Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Tranquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"key":"3189_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejrad.2008.01.026","volume":"2008","author":"JL Abraham","year":"2008","unstructured":"Abraham JL, Thakral C (2008) Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol 2008:66. https:\/\/doi.org\/10.1016\/j.ejrad.2008.01.026","journal-title":"Eur J Radiol"},{"key":"3189_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08335.x","author":"JL Abraham","year":"2008","unstructured":"Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P (2008) Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08335.x","journal-title":"Br J Dermatol"},{"key":"3189_CR3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2011.03.001","author":"AK Abu-Alfa","year":"2011","unstructured":"Abu-Alfa AK (2011) Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. https:\/\/doi.org\/10.1053\/j.ackd.2011.03.001","journal-title":"Adv Chronic Kidney Dis"},{"key":"3189_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2214\/AJR.09.3099","volume":"194","author":"HH Abujudeh","year":"2010","unstructured":"Abujudeh HH, Kosaraju VK, Kaewlai R (2010) Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. Am J Roentgenol 194:430\u2013434. https:\/\/doi.org\/10.2214\/AJR.09.3099","journal-title":"Am J Roentgenol"},{"key":"3189_CR5","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021210892","author":"H Akai","year":"2021","unstructured":"Akai H, Miyagawa K, Takahashi K, Mochida-Saito A, Kurokawa K, Takeda H et al (2021) Effects of gadolinium deposition in the brain on motor or behavioral function: a mouse model. Radiology. https:\/\/doi.org\/10.1148\/radiol.2021210892","journal-title":"Radiology"},{"key":"3189_CR6","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.5858\/2006-130-1354-agcmna","volume":"130","author":"H Akgun","year":"2006","unstructured":"Akgun H, Gonlusen G, Cartwright J, Suki WN, Truong LD (2006) Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med 130:1354\u20131357. https:\/\/doi.org\/10.5858\/2006-130-1354-agcmna","journal-title":"Arch Pathol Lab Med"},{"key":"3189_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2019.00001","volume":"11","author":"R Aldea","year":"2019","unstructured":"Aldea R, Weller RO, Wilcock DM, Carare RO, Richardson G (2019) Cerebrovascular smooth muscle cells as the drivers of intramural periarterial drainage of the brain. Front Aging Neurosci 11:1. https:\/\/doi.org\/10.3389\/fnagi.2019.00001","journal-title":"Front Aging Neurosci"},{"key":"3189_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1148\/RADIOL.2020192645","volume":"297","author":"SM Alkhunizi","year":"2020","unstructured":"Alkhunizi SM, Fakhoury M, Abou-Kheir W, Lawand N (2020) Gadolinium retention in the central and peripheral nervous system: Implications for pain, cognition, and neurogenesis. Radiology 297:407\u2013416. https:\/\/doi.org\/10.1148\/RADIOL.2020192645","journal-title":"Radiology"},{"key":"3189_CR9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1148\/radiol.2019182916","volume":"292","author":"H Attari","year":"2019","unstructured":"Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR (2019) A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis. Radiology 292:376\u2013386. https:\/\/doi.org\/10.1148\/radiol.2019182916","journal-title":"Radiology"},{"key":"3189_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00004424-199101000-00007","volume":"26","author":"R Battenfeld","year":"1991","unstructured":"Battenfeld R, El Rahman Khater A, Drommer W, Guenzel P, Kaup FJ (1991) Ioxaglate\u2013induced light and electron microscopic alterations in the renal proximal tubular epithelium of rats. Invest Radiol 26:35\u201339. https:\/\/doi.org\/10.1097\/00004424-199101000-00007","journal-title":"Invest Radiol"},{"key":"3189_CR11","unstructured":"Bayer HealthCare Pharmaceuticals (2011) Gadavist (gadobutrol) [package insert]. US Food and Drug Administration. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/201277s000lbl.pdf. Accessed 12 Sep 2021"},{"key":"3189_CR12","unstructured":"Bayer HealthCare Pharmaceuticals (2014) Magnevist (gadopentetate dimeglumine) [package insert]. US Food and Drug Administration. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019596s057lbl.pdf. Accessed 12 Sep 2021"},{"key":"3189_CR13","unstructured":"Bayer HealthCare Pharmaceuticals (2018) Eovist (gadoxetate disodium) [package insert]. US Food and Drug Administration. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022090s016lbl.pdf. Accessed 12 Sep 2021"},{"key":"3189_CR14","first-page":"286","volume":"2018","author":"AH Behzadi","year":"2018","unstructured":"Behzadi AH, Zhao Y, Farooq Z, Prince MR (2018) Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology 2018:286","journal-title":"Radiology"},{"key":"3189_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.berh.2012.07.008","volume":"26","author":"EJ Bernstein","year":"2012","unstructured":"Bernstein EJ, Schmidt-Lauber C, Kay J (2012) Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol 26:489\u2013503","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3189_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/RLI.0b013e3181a4d7e9","volume":"44","author":"N Bhagavathula","year":"2009","unstructured":"Bhagavathula N, Dasilva M, Aslam MN, Dame MK, Warner RL, Xu Y, Fisher GJ, Johnson KJ, Swartz R, Varani J (2009) Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol 44:433. https:\/\/doi.org\/10.1097\/RLI.0b013e3181a4d7e9","journal-title":"Invest Radiol"},{"key":"3189_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.juro.2008.05.005","volume":"180","author":"G Bhave","year":"2008","unstructured":"Bhave G, Lewis JB, Chang SS (2008) Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 180:830\u2013835","journal-title":"J Urol"},{"key":"3189_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1148\/radiol.2017170391","volume":"285","author":"A Bj\u00f8rnerud","year":"2017","unstructured":"Bj\u00f8rnerud A, Vatnehol SAS, Larsson C, Due-T\u00f8nnessen P, Hol PK, Groote IR (2017) Signal enhancement of the dentate nucleus at unenhanced MR imaging after very high cumulative doses of the macrocyclic gadolinium-based contrast agent gadobutrol: An observational study. Radiology 285:433\u2013444. https:\/\/doi.org\/10.1148\/radiol.2017170391","journal-title":"Radiology"},{"key":"3189_CR19","first-page":"151","volume":"4","author":"E Blaurock-Busch","year":"2019","unstructured":"Blaurock-Busch E (2019) Chelation and gadolinium: how effective is it? Diagn Pathol 4:151","journal-title":"Diagn Pathol"},{"key":"3189_CR20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1103\/PhysRev.73.679","volume":"73","author":"N Bloembergen","year":"1948","unstructured":"Bloembergen N, Purcell EM, Pound RV (1948) Relaxation effects in nuclear magnetic resonance absorption. Phys Rev 73:679. https:\/\/doi.org\/10.1103\/PhysRev.73.679","journal-title":"Phys Rev"},{"key":"3189_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136563","volume":"10","author":"C Bose","year":"2015","unstructured":"Bose C, Megyesi JK, Shah SV, Hiatt KM, Hall KA, Karaduta O et al (2015) Evidence suggesting a role of iron in a mouse model of nephrogenic systemic fibrosis. PLoS ONE 10:e136563. https:\/\/doi.org\/10.1371\/journal.pone.0136563","journal-title":"PLoS ONE"},{"key":"3189_CR22","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/0306-4522(82)90019-7","volume":"7","author":"GW Bourne","year":"1982","unstructured":"Bourne GW, Trifar\u00f3 JM (1982) The gadolinium ion: a potent blocker of calcium channels and catecholamine release from cultured chromaffin cells. Neuroscience 7:1615\u20131622. https:\/\/doi.org\/10.1016\/0306-4522(82)90019-7","journal-title":"Neuroscience"},{"key":"3189_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jaad.2008.01.025","volume":"59","author":"AS Boyd","year":"2008","unstructured":"Boyd AS, Sanyal S, Abraham JL (2008) Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. J Am Acad Dermatol 59:356\u2013363. https:\/\/doi.org\/10.1016\/j.jaad.2008.01.025","journal-title":"J Am Acad Dermatol"},{"key":"3189_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/RLI.0000000000000522","volume":"54","author":"J Boyken","year":"2019","unstructured":"Boyken J, Frenzel T, Lohrke J, Jost G, Sch\u00fctz G, Pietsch H (2019) Impact of treatment with chelating agents depends on the stability of administered GBCAs: a comparative study in rats. Invest Radiol 54:76. https:\/\/doi.org\/10.1097\/RLI.0000000000000522","journal-title":"Invest Radiol"},{"key":"3189_CR25","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s00330-002-1546-4","volume":"13","author":"A Bozzao","year":"2003","unstructured":"Bozzao A, Floris R, Fasoli F, Fantozzi LM, Colonnese C, Simonetti G (2003) Cerebrospinal fluid changes after intravenous injection of gadolinium chelate: assessment by FLAIR MR imaging. Eur Radiol 13:592\u2013597. https:\/\/doi.org\/10.1007\/s00330-002-1546-4","journal-title":"Eur Radiol"},{"key":"3189_CR26","unstructured":"Bracco Diagnostics (2010) MultiHance (gadobenate dimeglumine) [package insert]. US Food and Drug Administration. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021357s009lbl.pdf. Accessed 12 Sep 2021"},{"key":"3189_CR27","unstructured":"Bracco Diagnostics (2013) ProHance (gadoteridol) [package insert]. US Food and Drug Administration. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020131s026,021489s003lbl.pdf. Accessed 12 Sep 2021"},{"key":"3189_CR28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/00004424-199403000-00016","volume":"29","author":"G Brillet","year":"1994","unstructured":"Brillet G, Dubois M, Beaufils H, Bourbouze R, Deray G (1994) Renal tolerance of gadolinium-dota and gadolinium-dtpa in rats. Invest Radiol 29:352\u2013354. https:\/\/doi.org\/10.1097\/00004424-199403000-00016","journal-title":"Invest Radiol"},{"key":"3189_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12968-015-0168-3","volume":"17","author":"O Bruder","year":"2015","unstructured":"Bruder O, Schneider S, Pilz G, Van Rossum AC, Schwitter J, Nothnagel D et al (2015) 2015 update on acute adverse reactions to gadolinium based contrast agents in cardiovascular MR. Large multi-national and multi-ethnical population experience with 37788 patients from the EuroCMR registry. J Cardiovasc Magn Reson 17:1\u20137. https:\/\/doi.org\/10.1186\/s12968-015-0168-3","journal-title":"J Cardiovasc Magn Reson"},{"key":"3189_CR30","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.mri.2016.05.005","volume":"34","author":"LMB Burke","year":"2016","unstructured":"Burke LMB, Ramalho M, AlObaidy M, Chang E, Jay M, Semelka RC (2016) Self-reported gadolinium toxicity: a survey of patients with chronic symptoms. Magn Reson Imaging 34:1078\u20131080. https:\/\/doi.org\/10.1016\/j.mri.2016.05.005","journal-title":"Magn Reson Imaging"},{"key":"3189_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.25822","author":"S Bussi","year":"2018","unstructured":"Bussi S, Coppo A, Botteron C, Fraimbault V, Fanizzi A, De Laurentiis E et al (2018a) Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats. J Magn Reson Imaging. https:\/\/doi.org\/10.1002\/jmri.25822","journal-title":"J Magn Reson Imaging"},{"key":"3189_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.12.016","author":"S Bussi","year":"2018","unstructured":"Bussi S, Penard L, Bonaf\u00e8 R, Botteron C, Celeste R, Coppo A et al (2018b) Non-clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance\u00ae) to neonatal and juvenile rats. Regul Toxicol Pharmacol. https:\/\/doi.org\/10.1016\/j.yrtph.2017.12.016","journal-title":"Regul Toxicol Pharmacol"},{"key":"3189_CR250","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13244-019-0824-5","volume":"11","author":"S Bussi","year":"2020","unstructured":"Bussi S, Coppo A, Celeste R, Fanizzi A, Fringuello Mingo A, Ferraris A, Botteron C, Kirchin M, Tedoldi F (2020) Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats. Insights Imag 11:11. https:\/\/doi.org\/10.1186\/s13244-019-0824-5","journal-title":"Insights Imag"},{"key":"3189_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0730-725X(90)90055-7","volume":"8","author":"WP Cacheris","year":"1990","unstructured":"Cacheris WP, Quay SC, Rocklage SM (1990) The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 8:467\u2013481. https:\/\/doi.org\/10.1016\/0730-725X(90)90055-7","journal-title":"Magn Reson Imaging"},{"key":"3189_CR34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2214\/AJR.15.15327","volume":"206","author":"Y Cao","year":"2016","unstructured":"Cao Y, Huang DQ, Shih G, Prince MR (2016a) Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. Am J Roentgenol 206:414\u2013419. https:\/\/doi.org\/10.2214\/AJR.15.15327","journal-title":"Am J Roentgenol"},{"key":"3189_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/RLI.0000000000000294","volume":"51","author":"Y Cao","year":"2016","unstructured":"Cao Y, Zhang Y, Shih G, Bohmart A, Hecht EM, Prince MR (2016b) Effect of renal function on gadolinium-related signal increases on unenhanced t1-weighted brain magnetic resonance imaging. Invest Radiol 51:677\u2013682. https:\/\/doi.org\/10.1097\/RLI.0000000000000294","journal-title":"Invest Radiol"},{"key":"3189_CR36","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1021\/cr980440x","volume":"99","author":"P Caravan","year":"1999","unstructured":"Caravan P, Ellison JJ, McMurry TJ, Lauffer RB (1999) Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications. Chem Rev 99:2293\u20132353. https:\/\/doi.org\/10.1021\/cr980440x","journal-title":"Chem Rev"},{"key":"3189_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/00004424-199303001-00003","volume":"28","author":"CA Chang","year":"1993","unstructured":"Chang CA (1993) Magnetic resonance imaging contrast agents: design and physicochemical properties of gadodiamide. Invest Radiol 28:21\u201327. https:\/\/doi.org\/10.1097\/00004424-199303001-00003","journal-title":"Invest Radiol"},{"key":"3189_CR38","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/0960327112450897","volume":"31","author":"CC Chien","year":"2012","unstructured":"Chien CC, Sheu MJ, Chu CC, Sun YM, Kan WC, Wang HY et al (2012) Prophylactic 0.9% saline hydration inhibited high-dose gadodiamide-induced nephropathy in rats. Hum Exp Toxicol 31:1170\u20131178. https:\/\/doi.org\/10.1177\/0960327112450897","journal-title":"Hum Exp Toxicol"},{"key":"3189_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2009.12.044","volume":"64","author":"KN Christensen","year":"2011","unstructured":"Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR (2011) Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 64:91\u201396. https:\/\/doi.org\/10.1016\/j.jaad.2009.12.044","journal-title":"J Am Acad Dermatol"},{"key":"3189_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1148\/radiol.2451070353","volume":"245","author":"TA Collidge","year":"2007","unstructured":"Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris STW, Simpson K, Roditi GH (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: Retrospective study of a renal replacement therapy cohort. Radiology 245:168\u2013175. https:\/\/doi.org\/10.1148\/radiol.2451070353","journal-title":"Radiology"},{"key":"3189_CR41","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1007\/s00330-017-4810-3","volume":"27","author":"G Conte","year":"2017","unstructured":"Conte G, Preda L, Cocorocchio E, Raimondi S, Giannitto C, Minotti M et al (2017) Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. Eur Radiol 27:4372\u20134378. https:\/\/doi.org\/10.1007\/s00330-017-4810-3","journal-title":"Eur Radiol"},{"key":"3189_CR42","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","volume":"356","author":"SE Cowper","year":"2000","unstructured":"Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000\u20131001. https:\/\/doi.org\/10.1016\/S0140-6736(00)02694-5","journal-title":"Lancet"},{"key":"3189_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00000372-200110000-00001","volume":"23","author":"SE Cowper","year":"2001","unstructured":"Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23:383\u2013393. https:\/\/doi.org\/10.1097\/00000372-200110000-00001","journal-title":"Am J Dermatopathol"},{"key":"3189_CR44","first-page":"97","volume":"9","author":"R Damadian","year":"1977","unstructured":"Damadian R, Goldsmith M, Minkoff L (1977) NMR in cancer: XVI. FONAR image of the live human body. Physiol Chem Phys 9:97\u2013100","journal-title":"Physiol Chem Phys"},{"key":"3189_CR45","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/mrm.28060","volume":"83","author":"NM Damme","year":"2020","unstructured":"Damme NM, Fernandez DP, Wang LM, Wu Q, Kirk RA, Towner RA et al (2020) Analysis of retention of gadolinium by brain, bone, and blood following linear gadolinium-based contrast agent administration in rats with experimental sepsis. Magn Reson Med 83:1930\u20131939. https:\/\/doi.org\/10.1002\/mrm.28060","journal-title":"Magn Reson Med"},{"key":"3189_CR46","doi-asserted-by":"publisher","DOI":"10.1039\/b905145g","author":"TH Darrah","year":"2009","unstructured":"Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE (2009) Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics. https:\/\/doi.org\/10.1039\/b905145g","journal-title":"Metallomics"},{"key":"3189_CR47","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1148\/radiol.12120253","volume":"266","author":"MS Davenport","year":"2013","unstructured":"Davenport MS, Dillman JR, Cohan RH, Hussain HK, Khalatbari S, McHugh JB et al (2013) Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology 266:773\u2013782. https:\/\/doi.org\/10.1148\/radiol.12120253","journal-title":"Radiology"},{"key":"3189_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-93147-2","volume":"11","author":"J Davies","year":"2021","unstructured":"Davies J, Marino M, Smith APL, Crowder JM, Larsen M, Lowery L et al (2021) Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure. Sci Rep 11:1\u201312. https:\/\/doi.org\/10.1038\/s41598-021-93147-2","journal-title":"Sci Rep"},{"key":"3189_CR49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/RLI.0000000000000533","volume":"54","author":"K Deike-Hofmann","year":"2019","unstructured":"Deike-Hofmann K, Reuter J, Haase R, Paech D, Gnirs R, Bickelhaupt S et al (2019) Glymphatic pathway of gadolinium-based contrast agents through the brain: overlooked and misinterpreted. Invest Radiol 54:229\u2013237. https:\/\/doi.org\/10.1097\/RLI.0000000000000533","journal-title":"Invest Radiol"},{"key":"3189_CR50","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1136\/ard.2010.134858","volume":"69","author":"F Del Galdo","year":"2010","unstructured":"Del Galdo F, Wermuth PJ, Addya S, Fortina P, Jimenez SA (2010) NF\u03baB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 69:2024\u20132033. https:\/\/doi.org\/10.1136\/ard.2010.134858","journal-title":"Ann Rheum Dis"},{"key":"3189_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/RLI.0000000000000423","volume":"53","author":"E Di Gregorio","year":"2018","unstructured":"Di Gregorio E, Ferrauto G, Furlan C, Lanzardo S, Nuzzi R, Gianolio E et al (2018) The issue of gadolinium retained in tissues: insights on the role of metal complex stability by comparing metal uptake in murine tissues upon the concomitant administration of lanthanum-A and gadolinium-diethylentriamminopentaacetate. Invest Radiol 53:167\u2013172. https:\/\/doi.org\/10.1097\/RLI.0000000000000423","journal-title":"Invest Radiol"},{"key":"3189_CR52","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2214\/AJR.07.2554","volume":"189","author":"JR Dillman","year":"2007","unstructured":"Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC (2007) Frequency and severity of acute allergic-like reactions to gadolinium-containing IV contrast media in children and adults. Am J Roentgenol 189:1533\u20131538. https:\/\/doi.org\/10.2214\/AJR.07.2554","journal-title":"Am J Roentgenol"},{"key":"3189_CR53","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1152\/ajprenal.00379.2014","volume":"307","author":"C Do","year":"2014","unstructured":"Do C, Barnes JL, Tan C, Wagner B (2014) Type of MRI contrast, tissue gadolinium, and fibrosis. Am J Physiol Ren Physiol 307:844\u2013855. https:\/\/doi.org\/10.1152\/ajprenal.00379.2014","journal-title":"Am J Physiol Ren Physiol"},{"issue":"1","key":"3189_CR54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.34067\/kid.0000272019","volume":"360","author":"C Do","year":"2020","unstructured":"Do C, DeAguero J, Brearley A, Trejo X, Howard T, Escobar GP et al (2020) Gadolinium-based contrast agent use, their safety, and practice evolution. Kidney 360(1):10\u201334067. https:\/\/doi.org\/10.34067\/kid.0000272019","journal-title":"Kidney"},{"issue":"Suppl. 399","key":"3189_CR55","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/0284185195036S39924","volume":"36","author":"M Dobrota","year":"1995","unstructured":"Dobrota M, Powell CJ, Holtz E, Wallin A, Vik H (1995) Biochemical and morphological effects of contrast media on the kidney. Acta Radiol 36(Suppl. 399):196\u2013203","journal-title":"Acta Radiol"},{"key":"3189_CR56","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/RLI.0b013e318137a471","volume":"42","author":"O D\u00f6hr","year":"2007","unstructured":"D\u00f6hr O, Hofmeister R, Treher M, Schweinfurth H (2007) Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Invest Radiol 42:830\u2013841. https:\/\/doi.org\/10.1097\/RLI.0b013e318137a471","journal-title":"Invest Radiol"},{"key":"3189_CR57","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/path.2311","volume":"214","author":"M Edward","year":"2008","unstructured":"Edward M, Quinn JA, Mukherjee S, Jensen MBV, Jardine AG, Mark PB, Burden AD (2008) Gadodiamide contrast agent \u201cactivates\u201d fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 214:584\u2013593. https:\/\/doi.org\/10.1002\/path.2311","journal-title":"J Pathol"},{"key":"3189_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-25666-4","volume":"8","author":"PK Eide","year":"2018","unstructured":"Eide PK, Vatnehol SAS, Emblem KE, Ringstad G (2018) Magnetic resonance imaging provides evidence of glymphatic drainage from human brain to cervical lymph nodes. Sci Rep 8:1\u201310. https:\/\/doi.org\/10.1038\/s41598-018-25666-4","journal-title":"Sci Rep"},{"key":"3189_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/ndtplus\/sfq028","volume":"3","author":"TR Elmholdt","year":"2010","unstructured":"Elmholdt TR, J\u00f8rgensen B, Ramsing M, Pedersen M, Olesen AB (2010) Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT plus 3:285\u2013287. https:\/\/doi.org\/10.1093\/ndtplus\/sfq028","journal-title":"NDT plus"},{"key":"3189_CR60","doi-asserted-by":"publisher","DOI":"10.1080\/02841850701663442","author":"B Elmst\u00e5hl","year":"2007","unstructured":"Elmst\u00e5hl B, Leander P, Grant D, Doughty RW, Chai CM, Bj\u00f6rk J et al (2007) Histomorphological changes after renal X-ray arteriography using iodine and gadolinium contrast media in an ischemic porcine model. Acta Radiol. https:\/\/doi.org\/10.1080\/02841850701663442","journal-title":"Acta Radiol"},{"key":"3189_CR61","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00281-009-0177-0","volume":"31","author":"B Engelhardt","year":"2009","unstructured":"Engelhardt B, Sorokin L (2009) The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 31:497\u2013511","journal-title":"Semin Immunopathol"},{"key":"3189_CR62","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/RLI.0000000000000072","volume":"49","author":"Y Errante","year":"2014","unstructured":"Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Zobel BB, Quattrocchi CC (2014) Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 49:685\u2013690. https:\/\/doi.org\/10.1097\/RLI.0000000000000072","journal-title":"Invest Radiol"},{"key":"3189_CR63","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2214\/AJR.14.13430","volume":"204","author":"S Fakhran","year":"2015","unstructured":"Fakhran S, Alhilali L, Kale H, Kanal E (2015) Assessment of rates of acute adverse reactions to gadobenate dimeglumine: review of more than 130,000 administrations in 7.5 years. Am J Roentgenol 204:703\u2013706. https:\/\/doi.org\/10.2214\/AJR.14.13430","journal-title":"Am J Roentgenol"},{"key":"3189_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2010.04.003","author":"X Feng","year":"2010","unstructured":"Feng X, Xia Q, Yuan L, Yang X, Wang K (2010) Impaired mitochondrial function and oxidative stress in rat cortical neurons: Implications for gadolinium-induced neurotoxicity. Neurotoxicology. https:\/\/doi.org\/10.1016\/j.neuro.2010.04.003","journal-title":"Neurotoxicology"},{"key":"3189_CR65","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00401-018-1857-4","volume":"136","author":"S Fingerhut","year":"2018","unstructured":"Fingerhut S, Sperling M, Holling M, Niederstadt T, Allkemper T, Radbruch A et al (2018) Gadolinium-based contrast agents induce gadolinium deposits in cerebral vessel walls, while the neuropil is not affected: an autopsy study. Acta Neuropathol 136:391\u2013398. https:\/\/doi.org\/10.1007\/s00401-018-1857-4","journal-title":"Acta Neuropathol"},{"key":"3189_CR66","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3174\/ajnr.A5211","volume":"38","author":"Y Forslin","year":"2017","unstructured":"Forslin Y, Shams S, Hashim F, Aspelin P, Bergendal G, Martola J et al (2017) Retention of gadolinium-based contrast agents in multiple sclerosis: retrospective analysis of an 18-year longitudinal study. Am J Neuroradiol 38:1311\u20131316. https:\/\/doi.org\/10.3174\/ajnr.A5211","journal-title":"Am J Neuroradiol"},{"key":"3189_CR67","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/RLI.0b013e3181852171","volume":"43","author":"T Frenzel","year":"2008","unstructured":"Frenzel T, Lengsfeld P, Schirmer H, H\u00fctter J, Weinmann HJ (2008) Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37\u00b0C. Invest Radiol 43:817\u2013828. https:\/\/doi.org\/10.1097\/RLI.0b013e3181852171","journal-title":"Invest Radiol"},{"key":"3189_CR68","doi-asserted-by":"publisher","DOI":"10.1097\/rli.0000000000000517","author":"N Fretellier","year":"2019","unstructured":"Fretellier N, Granottier A, Rasschaert M, Grindel A-L, Baudimont F, Robert P et al (2019) Does age interfere with gadolinium toxicity and presence in brain and bone tissues? Invest Radiol. https:\/\/doi.org\/10.1097\/rli.0000000000000517","journal-title":"Invest Radiol"},{"key":"3189_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtemb.2021.126831","volume":"68","author":"C Furlan","year":"2021","unstructured":"Furlan C, Montarolo F, Di Gregorio E, Parolisi R, Atlante S, Buffo A et al (2021) Analysis of the gadolinium retention in the experimental autoimmune encephalomyelitis (EAE) murine model of multiple sclerosis. J Trace Elem Med Biol 68:126831. https:\/\/doi.org\/10.1016\/j.jtemb.2021.126831","journal-title":"J Trace Elem Med Biol"},{"key":"3189_CR70","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jamadermatol.2014.2660","volume":"151","author":"RM Gathings","year":"2015","unstructured":"Gathings RM, Reddy R, Cruz DS, Brodell RT (2015) Gadolinium-associated plaques: a new, distinctive clinical entity. JAMA Dermatol 151:316\u2013319. https:\/\/doi.org\/10.1001\/jamadermatol.2014.2660","journal-title":"JAMA Dermatol"},{"key":"3189_CR71","unstructured":"GE Healthcare (2010) Omniscan (gadodiamide) [package insert]. US Food and Drug Administration. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020123s037lbl.pdf. Accessed 12 Sep 2021"},{"key":"3189_CR72","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/j.1365-2133.2010.09918.x","volume":"163","author":"SJ George","year":"2010","unstructured":"George SJ, Webb SM, Abraham JL, Cramer SP (2010) Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 163:1077\u20131081. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09918.x","journal-title":"Br J Dermatol"},{"key":"3189_CR73","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00775-011-0757-z","volume":"16","author":"AJ Ghio","year":"2011","unstructured":"Ghio AJ, Soukup JM, Dailey LA, Richards J, Deng Z, Abraham JL (2011) Gadolinium exposure disrupts iron homeostasis in cultured cells. J Biol Inorg Chem 16:567\u2013575. https:\/\/doi.org\/10.1007\/s00775-011-0757-z","journal-title":"J Biol Inorg Chem"},{"key":"3189_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/3918292","volume":"2016","author":"V Granata","year":"2016","unstructured":"Granata V, Cascella M, Fusco R, Dell\u2019Aprovitola N, Catalano O, Filice S et al (2016) Immediate adverse reactions to gadolinium-based MR contrast media: a retrospective analysis on 10,608 examinations. Biomed Res Int 2016:1. https:\/\/doi.org\/10.1155\/2016\/3918292","journal-title":"Biomed Res Int"},{"key":"3189_CR75","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/02841850802637808","volume":"50","author":"D Grant","year":"2009","unstructured":"Grant D, Johnsen H, Juelsrud A, Lvhaug D (2009) Effects of gadolinium contrast agents in naive and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol 50:156\u2013169. https:\/\/doi.org\/10.1080\/02841850802637808","journal-title":"Acta Radiol"},{"key":"3189_CR76","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1148\/radiol.10100560","volume":"257","author":"SA Greenberg","year":"2010","unstructured":"Greenberg SA (2010) Zinc transmetallation and gadolinium retention after MR imaging: case report. Radiology 257:670\u2013673. https:\/\/doi.org\/10.1148\/radiol.10100560","journal-title":"Radiology"},{"key":"3189_CR77","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","volume":"21","author":"T Grobner","year":"2006","unstructured":"Grobner T (2006) Gadolinium\u2014a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104\u20131108. https:\/\/doi.org\/10.1093\/ndt\/gfk062","journal-title":"Nephrol Dial Transplant"},{"key":"3189_CR78","unstructured":"Guerbet (2017) Dotarem (gadoterate meglumine) [package insert]. US Food and Drug Administration. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/204781s001lbl.pdf. Accessed 12 Sep 2021"},{"key":"3189_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-79374-z","volume":"10","author":"J Habermeyer","year":"2020","unstructured":"Habermeyer J, Boyken J, Harrer J, Canneva F, Ratz V, Moceri S et al (2020) Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats. Sci Rep 10:1\u201314. https:\/\/doi.org\/10.1038\/s41598-020-79374-z","journal-title":"Sci Rep"},{"key":"3189_CR80","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1148\/radiology.195.3.7754011","volume":"195","author":"B Hamm","year":"1995","unstructured":"Hamm B, Staks T, M\u00fchler A, Bollow M, Taupitz M, Frenzel T et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785\u2013792. https:\/\/doi.org\/10.1148\/radiology.195.3.7754011","journal-title":"Radiology"},{"key":"3189_CR81","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00004424-199303001-00004","volume":"28","author":"ES Harpur","year":"1993","unstructured":"Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H (1993) Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 28:28\u201343. https:\/\/doi.org\/10.1097\/00004424-199303001-00004","journal-title":"Invest Radiol"},{"key":"3189_CR82","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jaad.2006.10.047","volume":"56","author":"WA High","year":"2007","unstructured":"High WA, Ayers RA, Chandler J, Zito G, Cowper SE (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21\u201326. https:\/\/doi.org\/10.1016\/j.jaad.2006.10.047","journal-title":"J Am Acad Dermatol"},{"key":"3189_CR83","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaad.2009.07.018","volume":"62","author":"WA High","year":"2010","unstructured":"High WA, Ranville JF, Brown M, Punshon T, Lanzirotti A, Jackson BP (2010) Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. J Am Acad Dermatol 62:38\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2009.07.018","journal-title":"J Am Acad Dermatol"},{"key":"3189_CR84","first-page":"85","volume":"104","author":"S Hirano","year":"1996","unstructured":"Hirano S, Suzuki KT (1996) Exposure, metabolism, and toxicity of rare earths and related compounds. Environ Health Perspect 104:85\u201395","journal-title":"Environ Health Perspect"},{"key":"3189_CR85","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1259\/bjr.20160590","volume":"90","author":"N Hoggard","year":"2017","unstructured":"Hoggard N, Roditi GH (2017) T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition? Br J Radiol 90:1069","journal-title":"Br J Radiol"},{"key":"3189_CR86","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1472-8206.2006.00447.x","volume":"20","author":"JM Id\u00e9e","year":"2006","unstructured":"Id\u00e9e JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: A review. Fundam Clin Pharmacol 20:563\u2013576","journal-title":"Fundam Clin Pharmacol"},{"key":"3189_CR87","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1002\/art.20362","volume":"50","author":"SA Jim\u00e9nez","year":"2004","unstructured":"Jim\u00e9nez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, Haddad R, Shanahan JC (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor \u03b21 expression in affected skin. Arthritis Rheum 50:2660\u20132666. https:\/\/doi.org\/10.1002\/art.20362","journal-title":"Arthritis Rheum"},{"key":"3189_CR88","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1076-6332(98)80191-8","volume":"5","author":"P Joffe","year":"1998","unstructured":"Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5:491\u2013502. https:\/\/doi.org\/10.1016\/S1076-6332(98)80191-8","journal-title":"Acad Radiol"},{"key":"3189_CR89","doi-asserted-by":"publisher","first-page":"4","DOI":"10.29245\/2572.942x\/2018\/4.1194","volume":"3","author":"C Johanson","year":"2018","unstructured":"Johanson C (2018) Choroid plexus blood-CSF barrier: major player in brain disease modeling and neuromedicine. J Neurol Neuromedicine 3:4. https:\/\/doi.org\/10.29245\/2572.942x\/2018\/4.1194","journal-title":"J Neurol Neuromedicine"},{"key":"3189_CR90","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-016-4654-2","author":"G Jost","year":"2017","unstructured":"Jost G, Frenzel T, Lohrke J, Lenhard DC, Naganawa S, Pietsch H (2017) Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-016-4654-2","journal-title":"Eur Radiol"},{"key":"3189_CR91","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1148\/radiol.2018180135","volume":"290","author":"G Jost","year":"2019","unstructured":"Jost G, Frenzel T, Boyken J, Lohrke J, Nischwitz V, Pietsch H (2019) Long-term excretion of gadolinium-based contrast agents: linear versus macrocyclic agents in an experimental rat model. Radiology 290:340\u2013348. https:\/\/doi.org\/10.1148\/radiol.2018180135","journal-title":"Radiology"},{"key":"3189_CR92","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1148\/radiol.12112025","volume":"264","author":"JW Jung","year":"2012","unstructured":"Jung JW, Kang HR, Kim MH, Lee W, Min KU, Han MH et al (2012) Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 264:414\u2013422. https:\/\/doi.org\/10.1148\/radiol.12112025","journal-title":"Radiology"},{"key":"3189_CR93","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.mri.2016.08.017","volume":"34","author":"E Kanal","year":"2016","unstructured":"Kanal E (2016) Gadolinium based contrast agents (GBCA): safety overview after 3 decades of clinical experience. Magn Reson Imaging 34:1341\u20131345. https:\/\/doi.org\/10.1016\/j.mri.2016.08.017","journal-title":"Magn Reson Imaging"},{"key":"3189_CR94","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1148\/radiol.2015150805","volume":"275","author":"E Kanal","year":"2015","unstructured":"Kanal E, Tweedle MF (2015) Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 275:630\u2013634","journal-title":"Radiology"},{"key":"3189_CR95","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13131669","author":"T Kanda","year":"2014","unstructured":"Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. https:\/\/doi.org\/10.1148\/radiol.13131669","journal-title":"Radiology"},{"key":"3189_CR96","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015142690","author":"T Kanda","year":"2015","unstructured":"Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J et al (2015a) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. https:\/\/doi.org\/10.1148\/radiol.2015142690","journal-title":"Radiology"},{"key":"3189_CR97","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.14140364","author":"T Kanda","year":"2015","unstructured":"Kanda T, Osawa M, Oba H, Toyoda K, Kotoku J, Haruyama T et al (2015b) High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. https:\/\/doi.org\/10.1148\/radiol.14140364","journal-title":"Radiology"},{"key":"3189_CR98","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1259\/bjr.20170115","volume":"90","author":"T Kanda","year":"2017","unstructured":"Kanda T, Nakai Y, Hagiwara A, Oba H, Toyoda K, Furui S (2017) Distribution and chemical forms of gadolinium in the brain: a review. Br J Radiol 90:1079","journal-title":"Br J Radiol"},{"key":"3189_CR100","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/RLI.0000000000000295","volume":"51","author":"AAP Kartamihardja","year":"2016","unstructured":"Kartamihardja AAP, Nakajima T, Kameo S, Koyama H, Tsushima Y (2016a) Impact of impaired renal function on gadolinium retention after administration of gadolinium-based contrast agents in a mouse model. Invest Radiol 51:655\u2013660. https:\/\/doi.org\/10.1097\/RLI.0000000000000295","journal-title":"Invest Radiol"},{"key":"3189_CR101","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160509","author":"AAP Kartamihardja","year":"2016","unstructured":"Kartamihardja AAP, Nakajima T, Kameo S, Koyama H, Tsushima Y (2016b) Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model. Br J Radiol. https:\/\/doi.org\/10.1259\/bjr.20160509","journal-title":"Br J Radiol"},{"key":"3189_CR102","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMcpc0708697","volume":"358","author":"J Kay","year":"2008","unstructured":"Kay J, Bazari H, Avery LL, Koreishi AF (2008) Case records of the Massachusetts General Hospital. Case 6\u20132008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med 358:827\u2013838","journal-title":"N Engl J Med"},{"key":"3189_CR103","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000000417","author":"MA Khairinisa","year":"2018","unstructured":"Khairinisa MA, Takatsuru Y, Amano I, Erdene K, Nakajima T, Kameo S et al (2018) The effect of perinatal gadolinium-based contrast agents on adult mice behavior. Invest Radiol. https:\/\/doi.org\/10.1097\/RLI.0000000000000417","journal-title":"Invest Radiol"},{"key":"3189_CR104","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jaad.2008.04.010","volume":"59","author":"A Khurana","year":"2008","unstructured":"Khurana A, Greene JF, High WA (2008) Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 59:218\u2013224. https:\/\/doi.org\/10.1016\/j.jaad.2008.04.010","journal-title":"J Am Acad Dermatol"},{"key":"3189_CR105","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/s00330-010-1716-8","volume":"20","author":"GM Kindberg","year":"2010","unstructured":"Kindberg GM, Uran S, Friisk G, Martinsen I, Skotland T (2010) The fate of Gd and chelate following intravenous injection of gadodiamide in rats. Eur Radiol 20:1636\u20131643. https:\/\/doi.org\/10.1007\/s00330-010-1716-8","journal-title":"Eur Radiol"},{"key":"3189_CR106","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00234-019-02172-6","volume":"61","author":"A Kiviniemi","year":"2019","unstructured":"Kiviniemi A, Gardberg M, Ek P, Frantz\u00e9n J, Bobacka J, Minn H (2019) Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear\/macrocyclic agents. Neuroradiology 61:535\u2013544. https:\/\/doi.org\/10.1007\/s00234-019-02172-6","journal-title":"Neuroradiology"},{"key":"3189_CR107","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/jnci\/djp514","volume":"102","author":"WM Klerkx","year":"2010","unstructured":"Klerkx WM, Bax L, Veldhuis WB, Heintz APM, Mali WP, Peeters PHM et al (2010) Detection of lymph node metastases by gadolinium-enhanced magnetic resonance imaging: systematic review and meta-analysis. J Natl Cancer Inst 102:244\u2013253. https:\/\/doi.org\/10.1093\/jnci\/djp514","journal-title":"J Natl Cancer Inst"},{"key":"3189_CR108","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021204320","author":"M Kobayashi","year":"2021","unstructured":"Kobayashi M, Levendovszky SR, Hippe DS, Hasegawa M, Murata N, Murata K et al (2021) Comparison of human tissue gadolinium retention and elimination between gadoteridol and gadobenate. Radiology. https:\/\/doi.org\/10.1148\/radiol.2021204320","journal-title":"Radiology"},{"key":"3189_CR110","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jacr.2007.08.014","volume":"5","author":"PH Kuo","year":"2008","unstructured":"Kuo PH (2008a) Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. J Am Coll Radiol 5:29\u201335","journal-title":"J Am Coll Radiol"},{"key":"3189_CR111","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.2214\/AJR.08.1179","volume":"191","author":"PH Kuo","year":"2008","unstructured":"Kuo PH (2008b) NSF-active and NSF-inert species of gadolinium: Mechanistic and clinical implications. Am J Roentgenol 191:1861\u20131863","journal-title":"Am J Roentgenol"},{"key":"3189_CR112","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1148\/radiol.2423061640","volume":"242","author":"PH Kuo","year":"2007","unstructured":"Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242:647\u2013649","journal-title":"Radiology"},{"key":"3189_CR113","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/RLI.0000000000000280","volume":"51","author":"E Lancelot","year":"2016","unstructured":"Lancelot E (2016) Revisiting the pharmacokinetic profiles of gadolinium-based contrast agents: differences in long-term biodistribution and excretion. Invest Radiol 51:691\u2013700","journal-title":"Invest Radiol"},{"key":"3189_CR114","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/jamadermatol.2015.0976","volume":"151","author":"KN Larson","year":"2015","unstructured":"Larson KN, Gagnon AL, Darling MD, Patterson JW, Cropley TG (2015) Nephrogenic systemic fibrosis manifesting a decade after exposure to gadolinium. JAMA Dermatol 151:1117\u20131120. https:\/\/doi.org\/10.1001\/jamadermatol.2015.0976","journal-title":"JAMA Dermatol"},{"key":"3189_CR115","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1021\/cr00081a003","volume":"87","author":"RB Lauffer","year":"1987","unstructured":"Lauffer RB (1987) Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 87:901\u2013927. https:\/\/doi.org\/10.1021\/cr00081a003","journal-title":"Chem Rev"},{"key":"3189_CR116","first-page":"752","volume":"1978","author":"PC Lauterbur","year":"1978","unstructured":"Lauterbur PC, Dias MHM, Rudin AM (1978) Augmentation of tissue water proton spin-lattice relaxation rates by in vivo addition of paramagnetic ions. Electrons Tissues 1978:752\u2013759","journal-title":"Electrons Tissues"},{"key":"3189_CR117","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/15563650.2019.1681442","volume":"58","author":"KA Layne","year":"2020","unstructured":"Layne KA, Wood DM, Dargan PI (2020) Gadolinium-based contrast agents\u2014what is the evidence for \u2018gadolinium deposition disease\u2019 and the use of chelation therapy? Clin Toxicol 58:151\u2013160","journal-title":"Clin Toxicol"},{"key":"3189_CR118","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/RLI.0000000000000762","volume":"56","author":"KA Layne","year":"2021","unstructured":"Layne KA, Raja K, Dargan PI, Wood DM (2021) Gadolinium concentrations in biological matrices from patients exposed to gadolinium-based contrast agents. Invest Radiol 56:458\u2013464. https:\/\/doi.org\/10.1097\/RLI.0000000000000762","journal-title":"Invest Radiol"},{"key":"3189_CR119","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1039\/c8mt00302e","volume":"11","author":"M Le Fur","year":"2019","unstructured":"Le Fur M, Caravan P (2019) The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists. Metallomics 11:240\u2013254. https:\/\/doi.org\/10.1039\/c8mt00302e","journal-title":"Metallomics"},{"key":"3189_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183916","volume":"12","author":"JY Lee","year":"2017","unstructured":"Lee JY, Park JE, Kim HS, Kim SO, Oh JY, Shim WH et al (2017) Up to 52 administrations of macrocyclic ionic MR contrast agent are not associated with intracranial gadolinium deposition: multifactorial analysis in 385 patients. PLoS ONE 12:e183916. https:\/\/doi.org\/10.1371\/journal.pone.0183916","journal-title":"PLoS ONE"},{"key":"3189_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-015-0275-4","volume":"33","author":"J Lohrke","year":"2016","unstructured":"Lohrke J, Frenzel T, Endrikat J, Alves FC, Grist TM, Law M et al (2016) 25 years of contrast-enhanced MRI: developments, current challenges and future perspectives. Adv Ther 33:1\u201328","journal-title":"Adv Ther"},{"key":"3189_CR122","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000000344","author":"J Lohrke","year":"2017","unstructured":"Lohrke J, Frisk AL, Frenzel T, Sch\u00f6ckel L, Rosenbruch M, Jost G et al (2017) Histology and gadolinium distribution in the rodent brain after the administration of cumulative high doses of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol. https:\/\/doi.org\/10.1097\/RLI.0000000000000344","journal-title":"Invest Radiol"},{"key":"3189_CR123","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1148\/radiol.2017171161","volume":"287","author":"ML Lord","year":"2018","unstructured":"Lord ML, Chettle DR, Gr\u00e4fe JL, Noseworthy MD, McNeill FE (2018) Observed deposition of gadolinium in bone using a new noninvasive in vivo biomedical device: results of a small pilot feasibility study. Radiology 287:96\u2013103. https:\/\/doi.org\/10.1148\/radiol.2017171161","journal-title":"Radiology"},{"key":"3189_CR124","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00004728-199911001-00023","volume":"23","author":"V Lorusso","year":"1999","unstructured":"Lorusso V, Arbughi T, Tirone P, De Ha\u00ebn C (1999) Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance\u00ae). J Comput Assist Tomogr 23:181\u2013194","journal-title":"J Comput Assist Tomogr"},{"key":"3189_CR125","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13181-018-0689-x","volume":"15","author":"T Lyapustina","year":"2019","unstructured":"Lyapustina T, Goldfine C, Rhyee S, Babu KM, Griswold MK (2019) Evaluating the patient with reported gadolinium-associated illness. J Med Toxicol 15:36\u201344","journal-title":"J Med Toxicol"},{"key":"3189_CR127","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1681\/ASN.2006060601","volume":"17","author":"P Marckmann","year":"2006","unstructured":"Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359\u20132362","journal-title":"J Am Soc Nephrol"},{"key":"3189_CR128","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/0730-725x(84)90080-8","volume":"4","author":"J Marie Caille","year":"1983","unstructured":"Marie Caille J, Lemanceau B, Bonnemain B (1983) Gadolinium as a contrast agent for NMR. Am J Neuroradiol 4:1041\u20131042. https:\/\/doi.org\/10.1016\/0730-725x(84)90080-8","journal-title":"Am J Neuroradiol"},{"key":"3189_CR129","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/cld.1024","volume":"17","author":"RM Marks","year":"2021","unstructured":"Marks RM, Ash RM, Lee JT (2021) Gadolinium deposition and liver MRI. Clin Liver Dis 17:129","journal-title":"Clin Liver Dis"},{"key":"3189_CR130","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1148\/radiol.2016152846","volume":"281","author":"N Maximova","year":"2016","unstructured":"Maximova N, Gregori M, Zennaro F, Sonzogni A, Simeone R, Zanon D (2016) Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology 281:418\u2013426. https:\/\/doi.org\/10.1148\/radiol.2016152846","journal-title":"Radiology"},{"key":"3189_CR131","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jmri.21983","volume":"30","author":"SM Mazhar","year":"2009","unstructured":"Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB (2009) Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 30:1313\u20131322","journal-title":"J Magn Reson Imaging"},{"key":"3189_CR132","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.15150025","author":"RJ McDonald","year":"2015","unstructured":"McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR et al (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. https:\/\/doi.org\/10.1148\/radiol.15150025","journal-title":"Radiology"},{"key":"3189_CR133","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jamapediatrics.2017.0264","volume":"171","author":"JS McDonald","year":"2017","unstructured":"McDonald JS, McDonald RJ, Jentoft ME, Paolini MA, Murray DL, Kallmes DF et al (2017a) Intracranial gadolinium deposition following gadodiamide-enhanced magnetic resonance imaging in pediatric patients: a case-control study. JAMA Pediatr 171:705\u2013707","journal-title":"JAMA Pediatr"},{"key":"3189_CR134","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1148\/radiol.2017161594","volume":"285","author":"RJ McDonald","year":"2017","unstructured":"McDonald RJ, McDonald JS, Dai D, Schroeder D, Jentoft ME, Murray DL et al (2017b) Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus macrocyclic gadolinium chelates. Radiology 285:536\u2013545. https:\/\/doi.org\/10.1148\/radiol.2017161594","journal-title":"Radiology"},{"key":"3189_CR135","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2017161595","author":"RJ McDonald","year":"2017","unstructured":"McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Paolini MA, Murray DL et al (2017c) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology. https:\/\/doi.org\/10.1148\/radiol.2017161595","journal-title":"Radiology"},{"key":"3189_CR136","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018181151","author":"RJ McDonald","year":"2018","unstructured":"McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH et al (2018) Gadolinium retention: a research roadmap from the 2018 NIH\/ACR\/RSNA workshop on gadolinium chelates. Radiology. https:\/\/doi.org\/10.1148\/radiol.2018181151","journal-title":"Radiology"},{"key":"3189_CR137","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1148\/radiol.2019182834","volume":"292","author":"JS McDonald","year":"2019","unstructured":"McDonald JS, Hunt CH, Kolbe AB, Schmitz JJ, Hartman RP, Maddox DE et al (2019) Acute adverse events following gadolinium-based contrast agent administration: a single-center retrospective study of 281 945 injections. Radiology 292:620\u2013627. https:\/\/doi.org\/10.1148\/radiol.2019182834","journal-title":"Radiology"},{"key":"3189_CR138","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.semarthrit.2005.08.002","volume":"35","author":"FA Mendoza","year":"2006","unstructured":"Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35:238\u2013249. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.08.002","journal-title":"Semin Arthritis Rheum"},{"key":"3189_CR139","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1148\/radiol.2019190461","volume":"294","author":"O Minaeva","year":"2020","unstructured":"Minaeva O, Hua N, Franz ES, Lupoli N, Mian AZ, Farris CW et al (2020) Nonhomogeneous gadolinium retention in the cerebral cortex after intravenous administration of gadolinium-based contrast agent in rats and humans. Radiology 294:377\u2013385. https:\/\/doi.org\/10.1148\/radiol.2019190461","journal-title":"Radiology"},{"key":"3189_CR140","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0720-048X(96)01085-6","volume":"23","author":"SK Morcos","year":"1996","unstructured":"Morcos SK, Epstein FH, Haylor J, Dobrota M (1996) Aspects of contrast media nephrotoxicity. Eur J Radiol 23:178\u2013184. https:\/\/doi.org\/10.1016\/S0720-048X(96)01085-6","journal-title":"Eur J Radiol"},{"key":"3189_CR141","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1148\/radiol.10100906","volume":"259","author":"DE Morgan","year":"2011","unstructured":"Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN (2011) Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28 078 patients. Radiology 259:109\u2013116. https:\/\/doi.org\/10.1148\/radiol.10100906","journal-title":"Radiology"},{"key":"3189_CR142","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00401-016-1555-z","volume":"131","author":"AWJ Morris","year":"2016","unstructured":"Morris AWJ, Sharp MMG, Albargothy NJ, Fernandes R, Hawkes CA, Verma A et al (2016) Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol 131:725\u2013733. https:\/\/doi.org\/10.1007\/s00401-016-1555-z","journal-title":"Acta Neuropathol"},{"key":"3189_CR143","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/RLI.0000000000000398","volume":"52","author":"A M\u00fcller","year":"2017","unstructured":"M\u00fcller A, Fries P, Jelvani B, Lux F, R\u00fcbe CE, Kremp S et al (2017) Magnetic resonance lymphography at 9.4 T using a gadolinium-based nanoparticle in rats: investigations in healthy animals and in a hindlimb lymphedema model. Invest Radiol 52:725\u2013733. https:\/\/doi.org\/10.1097\/RLI.0000000000000398","journal-title":"Invest Radiol"},{"key":"3189_CR144","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/RLI.0000000000000252","volume":"51","author":"N Murata","year":"2016","unstructured":"Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D et al (2016a) Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 51:447\u2013453. https:\/\/doi.org\/10.1097\/RLI.0000000000000252","journal-title":"Invest Radiol"},{"key":"3189_CR145","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.mri.2016.08.025","volume":"34","author":"N Murata","year":"2016","unstructured":"Murata N, Murata K, Gonzalez-Cuyar LF, Maravilla KR (2016b) Gadolinium tissue deposition in brain and bone. Magn Reson Imaging 34:1359\u20131366. https:\/\/doi.org\/10.1016\/j.mri.2016.08.025","journal-title":"Magn Reson Imaging"},{"key":"3189_CR146","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2214\/ajr.167.4.8819369","volume":"167","author":"KJ Murphy","year":"1996","unstructured":"Murphy KJ, Brunberg JA, Cohan RH (1996) Adverse reactions to gadolinium contrast media: a review of 36 cases. Am J Roentgenol 167:847\u2013849. https:\/\/doi.org\/10.2214\/ajr.167.4.8819369","journal-title":"Am J Roentgenol"},{"key":"3189_CR147","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1076-6332(99)80114-7","volume":"6","author":"KPJ Murphy","year":"1999","unstructured":"Murphy KPJ, Szopinski KT, Cohan RH, Mermillod B, Ellis JH (1999) Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology fellowship directors. Acad Radiol 6:656\u2013664","journal-title":"Acad Radiol"},{"key":"3189_CR148","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1148\/radiol.2018171105","volume":"288","author":"AK Nehra","year":"2018","unstructured":"Nehra AK, McDonald RJ, Bluhm AM, Gunderson TM, Murray DL, Jannetto PJ, Kallmes DF, Eckel LJJSM (2018a) Accumulation of gadolinium in human cerebrospinal fluid after gadobutrol-enhanced MR imaging: a prospective observational cohort study. Radiology 288:416\u2013423","journal-title":"Radiology"},{"key":"3189_CR149","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1148\/radiol.2018171105","volume":"288","author":"AK Nehra","year":"2018","unstructured":"Nehra AK, McDonald RJ, Bluhm AM, Gunderson TM, Murray DL, Jannetto PJ et al (2018b) Accumulation of gadolinium in human cerebrospinal fluid after gadobutrol-enhanced MR imaging: a prospective observational cohort study. Radiology 288:416\u2013423. https:\/\/doi.org\/10.1148\/radiol.2018171105","journal-title":"Radiology"},{"key":"3189_CR150","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1183\/09031936.93.03020202","volume":"3","author":"B Nemery","year":"1990","unstructured":"Nemery B (1990) Metal toxicity and the respiratory tract. Eur Respir J 3:202\u2013219","journal-title":"Eur Respir J"},{"key":"3189_CR151","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/jmri.21980","volume":"30","author":"BB Newton","year":"2009","unstructured":"Newton BB, Jimenez SA (2009) Mechanism of NSF: new evidence challenging the prevailing theory. J Magn Reson Imaging 30:1277\u20131283","journal-title":"J Magn Reson Imaging"},{"key":"3189_CR152","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/mrm.28249","volume":"84","author":"H Oh","year":"2020","unstructured":"Oh H, Chung YE, You JS, Joo CG, Kim PK, Lim JS et al (2020) Gadolinium retention in rat abdominal organs after administration of gadoxetic acid disodium compared to gadodiamide and gadobutrol. Magn Reson Med 84:2124\u20132132. https:\/\/doi.org\/10.1002\/mrm.28249","journal-title":"Magn Reson Med"},{"key":"3189_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2463\/mrms.2012-0051","volume":"13","author":"T Okigawa","year":"2014","unstructured":"Okigawa T, Utsunomiya D, Tajiri S, Okumura S, Sasao A, Wada H et al (2014) Incidence and severity of acute adverse reactions to four different gadolinium-based MR contrast agents. Magn Reson Med Sci 13:1\u20136. https:\/\/doi.org\/10.2463\/mrms.2012-0051","journal-title":"Magn Reson Med Sci"},{"key":"3189_CR154","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/jmri.1880030128","volume":"3","author":"AN Oksendal","year":"1993","unstructured":"Oksendal AN, Hals P-A (1993) Biodistribution and toxicity of MR imaging contrast media. J Magn Reson Imaging 3:157\u2013165","journal-title":"J Magn Reson Imaging"},{"key":"3189_CR155","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1111\/bjd.17398","volume":"180","author":"O Olayiwola","year":"2019","unstructured":"Olayiwola O, Ronkainen S, Miller D, High W, Farah RS (2019) Image gallery: a case of gadolinium-associated plaques requiring confirmation with mass spectrometry. Br J Dermatol 180:e66","journal-title":"Br J Dermatol"},{"key":"3189_CR156","doi-asserted-by":"publisher","first-page":"e171704","DOI":"10.1371\/journal.pone.0171704","volume":"12","author":"C Olchowy","year":"2017","unstructured":"Olchowy C, Cebulski K, \u0141asecki M, Chaber R, Olchowy A, Ka\u0142wak K et al (2017) The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity\u2014a systematic review. PLoS ONE 12:e171704","journal-title":"PLoS ONE"},{"key":"3189_CR157","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ecoenv.2015.01.030","volume":"115","author":"G Pagano","year":"2015","unstructured":"Pagano G, Guida M, Tommasi F, Oral R (2015) Health effects and toxicity mechanisms of rare earth elements-knowledge gaps and research prospects. Ecotoxicol Environ Saf 115:40\u201348","journal-title":"Ecotoxicol Environ Saf"},{"key":"3189_CR158","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/RLI.0000000000000528","volume":"54","author":"M Parillo","year":"2019","unstructured":"Parillo M, Sapienza M, Arpaia F, Magnani F, Mallio CA, D\u2019Alessio P et al (2019) A structured survey on adverse events occurring within 24 hours after intravenous exposure to gadodiamide or gadoterate meglumine: a controlled prospective comparison study. Invest Radiol 54:191\u2013197. https:\/\/doi.org\/10.1097\/RLI.0000000000000528","journal-title":"Invest Radiol"},{"key":"3189_CR159","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2215\/CJN.06011108","volume":"4","author":"MA Perazella","year":"2009","unstructured":"Perazella MA (2009) Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 4:461\u2013469","journal-title":"Clin J Am Soc Nephrol"},{"key":"3189_CR160","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-008-1259-4","author":"H Pietsch","year":"2009","unstructured":"Pietsch H, Lengsfeld P, Jost G, Frenzel T, H\u00fctter J, Sieber MA (2009) Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-008-1259-4","journal-title":"Eur Radiol"},{"key":"3189_CR161","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/RLI.0b013e3181efd49a","volume":"46","author":"H Pietsch","year":"2011","unstructured":"Pietsch H, Raschke M, Ellinger-Ziegelbauer H, Jost G, Walter J, Frenzel T et al (2011) The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol 46:48\u201356. https:\/\/doi.org\/10.1097\/RLI.0b013e3181efd49a","journal-title":"Invest Radiol"},{"key":"3189_CR162","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10534-008-9135-x","volume":"21","author":"M Port","year":"2008","unstructured":"Port M, Id\u00e9e JM, Medina C, Robic C, Sabatou M, Corot C (2008) Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 21:469\u2013490","journal-title":"Biometals"},{"key":"3189_CR163","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1148\/radiol.2016151066","volume":"281","author":"S Power","year":"2016","unstructured":"Power S, Talbot N, Kucharczyk W, Mandell DM (2016) Allergic-like reactions to the MR imaging contrast agent gadobutrol: a prospective study of 32 991 consecutive injections. Radiology 281:72\u201377. https:\/\/doi.org\/10.1148\/radiol.2016151066","journal-title":"Radiology"},{"key":"3189_CR164","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1148\/radiol.2483071863","volume":"248","author":"MR Prince","year":"2008","unstructured":"Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapaz RL, Lee HJ, Magro CM, Valeri AM (2008) Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248:807\u2013816. https:\/\/doi.org\/10.1148\/radiol.2483071863","journal-title":"Radiology"},{"key":"3189_CR165","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2214\/AJR.10.4885","volume":"196","author":"MR Prince","year":"2011","unstructured":"Prince MR, Zhang H, Zou Z, Staron RB, Brill PW (2011) Incidence of immediate gadolinium contrast media reactions. Am J Roentgenol 196:138\u2013143. https:\/\/doi.org\/10.2214\/AJR.10.4885","journal-title":"Am J Roentgenol"},{"key":"3189_CR166","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/j.ackd.2017.03.002","volume":"24","author":"JP Prybylski","year":"2017","unstructured":"Prybylski JP, Jay M (2017) The impact of excess ligand on the retention of nonionic, linear gadolinium-based contrast agents in patients with various levels of renal dysfunction: a review and simulation analysis. Adv Chronic Kidney Dis 24:176\u2013182","journal-title":"Adv Chronic Kidney Dis"},{"key":"3189_CR167","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00062-018-0678-0","volume":"28","author":"R Pullicino","year":"2018","unstructured":"Pullicino R, Radon M, Biswas S, Bhojak M, Das K (2018) A review of the current evidence on gadolinium deposition in the brain. Clin Neuroradiol 28:159\u2013169","journal-title":"Clin Neuroradiol"},{"key":"3189_CR168","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/jcb.240560115","volume":"56","author":"LD Quarles","year":"1994","unstructured":"Quarles LD, Hartle JE, Middleton JP, Zhang J, Arthur JM, Raymond JR (1994) Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. J Cell Biochem 56:106\u2013117. https:\/\/doi.org\/10.1002\/jcb.240560115","journal-title":"J Cell Biochem"},{"key":"3189_CR169","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/RLI.0000000000000154","volume":"50","author":"CC Quattrocchi","year":"2015","unstructured":"Quattrocchi CC, Mallio CA, Errante Y, Cirimele V, Carideo L, Ax A et al (2015) Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 50:470\u2013472. https:\/\/doi.org\/10.1097\/RLI.0000000000000154","journal-title":"Invest Radiol"},{"key":"3189_CR170","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1148\/radiol.2015150337","volume":"275","author":"A Radbruch","year":"2015","unstructured":"Radbruch A, Weberling LD, Kieslich PJ, Eidel O, Burth S, Kickingereder P et al (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275:783\u2013791. https:\/\/doi.org\/10.1148\/radiol.2015150337","journal-title":"Radiology"},{"key":"3189_CR171","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/radiol.2016162241","volume":"282","author":"A Radbruch","year":"2017","unstructured":"Radbruch A, Haase R, Kieslich PJ, Weberling LD, Kickingereder P, Wick W et al (2017) No signal intensity increase in the dentate nucleus on unenhanced t1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents. Radiology 282:699\u2013707. https:\/\/doi.org\/10.1148\/radiol.2016162241","journal-title":"Radiology"},{"key":"3189_CR172","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/RLI.0000000000000575","volume":"54","author":"A Radbruch","year":"2019","unstructured":"Radbruch A, Richter H, Fingerhut S, Martin LF, Xia A, Henze N et al (2019) Gadolinium deposition in the brain in a large animal model: comparison of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 54:531\u2013536. https:\/\/doi.org\/10.1097\/RLI.0000000000000575","journal-title":"Invest Radiol"},{"key":"3189_CR173","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/RLI.0000000000000677","volume":"55","author":"A Radbruch","year":"2020","unstructured":"Radbruch A, Richter H, B\u00fccker P, Berlandi J, Sch\u00e4nzer A, Deike-Hofmann K et al (2020) Is small fiber neuropathy induced by gadolinium-based contrast agents? Invest Radiol 55:473\u2013480. https:\/\/doi.org\/10.1097\/RLI.0000000000000677","journal-title":"Invest Radiol"},{"key":"3189_CR174","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1148\/radiol.2015150872","volume":"276","author":"J Ramalho","year":"2015","unstructured":"Ramalho J, Castillo M, AlObaidy M, Nunes RH, Ramalho M, Dale BM et al (2015) High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 276:836\u2013844. https:\/\/doi.org\/10.1148\/radiol.2015150872","journal-title":"Radiology"},{"key":"3189_CR175","doi-asserted-by":"publisher","DOI":"10.1097\/rli.0000000000000447","author":"M Rasschaert","year":"2018","unstructured":"Rasschaert M, Emerit A, Fretellier N, Factor C, Robert P, Id\u00e9e J-M et al (2018a) Gadolinium retention, brain T1 hyperintensity, and endogenous metals. Invest Radiol. https:\/\/doi.org\/10.1097\/rli.0000000000000447","journal-title":"Invest Radiol"},{"key":"3189_CR176","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/RLI.0000000000000490","volume":"53","author":"M Rasschaert","year":"2018","unstructured":"Rasschaert M, Schroeder JA, Di WuT, Marco S, Emerit A, Siegmund H et al (2018b) Multimodal imaging study of gadolinium presence in rat cerebellum: differences between Gd chelates, presence in the Virchow-Robin space, association with lipofuscin, and hypotheses about distribution pathway. Invest Radiol 53:518. https:\/\/doi.org\/10.1097\/RLI.0000000000000490","journal-title":"Invest Radiol"},{"key":"3189_CR177","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.27124","author":"M Rasschaert","year":"2020","unstructured":"Rasschaert M, Weller RO, Schroeder JA, Brochhausen C, Id\u00e9e JM (2020) Retention of gadolinium in brain parenchyma: pathways for speciation, access, and distribution. A critical review. J Magn Reson Imaging. https:\/\/doi.org\/10.1002\/jmri.27124","journal-title":"J Magn Reson Imaging"},{"key":"3189_CR178","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jama.2016.12126","volume":"316","author":"JG Ray","year":"2016","unstructured":"Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL (2016) Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA J Am Med Assoc 316:952\u2013961. https:\/\/doi.org\/10.1001\/jama.2016.12126","journal-title":"JAMA J Am Med Assoc"},{"key":"3189_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2045-8118-8-3","volume":"8","author":"Z Redzic","year":"2011","unstructured":"Redzic Z (2011) Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 8:1\u201325","journal-title":"Fluids Barriers CNS"},{"key":"3189_CR180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-22511-6","volume":"8","author":"JA Rees","year":"2018","unstructured":"Rees JA, Deblonde GJP, An DD, Ansoborlo C, Gauny SS, Abergel RJ (2018) Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents. Sci Rep 8:1\u20139. https:\/\/doi.org\/10.1038\/s41598-018-22511-6","journal-title":"Sci Rep"},{"key":"3189_CR181","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227649","volume":"15","author":"H Richter","year":"2020","unstructured":"Richter H, B\u00fccker P, Dunker C, Karst U, Kircher PR (2020) Gadolinium deposition in the brain of dogs after multiple intravenous administrations of linear gadolinium based contrast agents. PLoS ONE 15:e0227649. https:\/\/doi.org\/10.1371\/journal.pone.0227649","journal-title":"PLoS ONE"},{"key":"3189_CR182","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2214\/AJR.10.4392","volume":"195","author":"KI Ringe","year":"2010","unstructured":"Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium\u2014enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. Am J Roentgenol 195:13\u201328","journal-title":"Am J Roentgenol"},{"key":"3189_CR183","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/RLI.0000000000000181","volume":"50","author":"P Robert","year":"2015","unstructured":"Robert P, Lehericy S, Grand S, Violas X, Fretellier N, Ide\u00e9 JM et al (2015) T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol 50:473. https:\/\/doi.org\/10.1097\/RLI.0000000000000181","journal-title":"Invest Radiol"},{"key":"3189_CR184","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000000241","author":"P Robert","year":"2016","unstructured":"Robert P, Violas X, Grand S, Lehericy S, Id\u00e9e JM, Ballet S et al (2016) Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol. https:\/\/doi.org\/10.1097\/RLI.0000000000000241","journal-title":"Invest Radiol"},{"key":"3189_CR185","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018172746","author":"P Robert","year":"2018","unstructured":"Robert P, Fingerhut S, Factor C, Vives V, Letien J, Sperling M et al (2018) One-year retention of gadolinium in the brain: comparison of gadodiamide and gadoterate meglumine in a rodent model. Radiology. https:\/\/doi.org\/10.1148\/radiol.2018172746","journal-title":"Radiology"},{"key":"3189_CR186","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.3174\/ajnr.A4891","volume":"37","author":"DR Roberts","year":"2016","unstructured":"Roberts DR, Chatterjee AR, Yazdani M, Marebwa B, Brown T, Collins H et al (2016a) Pediatric patients demonstrate progressive t1-weighted hyperintensity in the dentate nucleus following multiple doses of gadolinium-based contrast agent. Am J Neuroradiol 37:2340\u20132347","journal-title":"Am J Neuroradiol"},{"key":"3189_CR187","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/RLI.0000000000000266","volume":"51","author":"DR Roberts","year":"2016","unstructured":"Roberts DR, Lindhorst SM, Welsh CT, Maravilla KR, Herring MN, Braun KA et al (2016b) High levels of gadolinium deposition in the skin of a patient with normal renal function. Invest Radiol 51:280\u2013289. https:\/\/doi.org\/10.1097\/RLI.0000000000000266","journal-title":"Invest Radiol"},{"key":"3189_CR188","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1525-139x.2007.00405.x","volume":"21","author":"RA Rodby","year":"2008","unstructured":"Rodby RA (2008) NSF: what we know and what we need to know: dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients. Semin Dial 21:145\u2013149. https:\/\/doi.org\/10.1111\/j.1525-139x.2007.00405.x","journal-title":"Semin Dial"},{"key":"3189_CR189","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1053\/j.ajkd.2020.07.012","volume":"77","author":"MR Rudnick","year":"2021","unstructured":"Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI (2021) Risks and options with gadolinium-based contrast agents in patients with CKD: a review. Am J Kidney Dis 77:517\u2013528","journal-title":"Am J Kidney Dis"},{"key":"3189_CR190","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1148\/radiology.147.3.6844614","volume":"147","author":"VM Runge","year":"1983","unstructured":"Runge VM, Stewart RG, Clanton JA, Jones MM, Lukehart CM, Partain CL et al (1983) Work in progress: potential oral and intravenous paramagnetic NMR contrast agents. Radiology 147:789\u2013791. https:\/\/doi.org\/10.1148\/radiology.147.3.6844614","journal-title":"Radiology"},{"key":"3189_CR191","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1093\/ndt\/gfr085","volume":"26","author":"S Sanyal","year":"2011","unstructured":"Sanyal S, Marckmann P, Scherer S, Abraham JL (2011) Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis\u2014an autopsy-based review. Nephrol Dial Transplant 26:3616\u20133626. https:\/\/doi.org\/10.1093\/ndt\/gfr085","journal-title":"Nephrol Dial Transplant"},{"key":"3189_CR192","doi-asserted-by":"publisher","first-page":"968","DOI":"10.2215\/CJN.00100108","volume":"3","author":"JA Schroeder","year":"2008","unstructured":"Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M et al (2008) Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 3:968\u2013975. https:\/\/doi.org\/10.2215\/CJN.00100108","journal-title":"Clin J Am Soc Nephrol"},{"key":"3189_CR193","first-page":"927","volume":"43","author":"G Schuhmann-Giampieri","year":"1993","unstructured":"Schuhmann-Giampieri G, Frenzel T, Schmitt-Willich H (1993) Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Arzneimittelforschung 43:927\u2013931","journal-title":"Arzneimittelforschung"},{"key":"3189_CR194","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1148\/radiology.183.1.1549695","volume":"183","author":"G Schuhmann-Giampieri","year":"2014","unstructured":"Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U (2014) Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183:59\u201364. https:\/\/doi.org\/10.1148\/radiology.183.1.1549695","journal-title":"Radiology"},{"key":"3189_CR195","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1155\/2013\/219840","volume":"2013","author":"ME Sears","year":"2013","unstructured":"Sears ME (2013) Chelation: harnessing and enhancing heavy metal detoxification\u2014a review. Sci World J 2013:5","journal-title":"Sci World J"},{"key":"3189_CR196","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/RLI.0000000000000318","volume":"51","author":"RC Semelka","year":"2016","unstructured":"Semelka RC, Commander CW, Jay M, Burke LMB, Ramalho M (2016a) Presumed gadolinium toxicity in subjects with normal renal function: a report of 4 cases. Invest Radiol 51:661\u2013665. https:\/\/doi.org\/10.1097\/RLI.0000000000000318","journal-title":"Invest Radiol"},{"key":"3189_CR197","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.mri.2016.07.016","volume":"34","author":"RC Semelka","year":"2016","unstructured":"Semelka RC, Ramalho J, Vakharia A, AlObaidy M, Burke LM, Jay M et al (2016b) Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magn Reson Imaging 34:1383\u20131390. https:\/\/doi.org\/10.1016\/j.mri.2016.07.016","journal-title":"Magn Reson Imaging"},{"key":"3189_CR198","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/RLI.0000000000000453","volume":"53","author":"RC Semelka","year":"2018","unstructured":"Semelka RC, Ramalho M, Jay M, Hickey L, Hickey J (2018) Intravenous calcium-\/zinc-diethylene triamine penta-acetic acid in patients with presumed gadolinium deposition disease: a preliminary report on 25 patients. Invest Radiol 53:373\u2013379. https:\/\/doi.org\/10.1097\/RLI.0000000000000453","journal-title":"Invest Radiol"},{"key":"3189_CR199","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1007\/s00330-008-0977-y","volume":"18","author":"MA Sieber","year":"2008","unstructured":"Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F et al (2008) Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 18:2164\u20132173. https:\/\/doi.org\/10.1007\/s00330-008-0977-y","journal-title":"Eur Radiol"},{"key":"3189_CR200","first-page":"1381","volume":"13","author":"G Simon","year":"1964","unstructured":"Simon G, Chatelanat F, Falbriard A (1964) Experimental nephrosis due to inulin: light and electron microscopic studies. Lab Invest 13:1381\u20131393","journal-title":"Lab Invest"},{"key":"3189_CR201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13244-019-0795-6","volume":"11","author":"B Simona","year":"2020","unstructured":"Simona B, Alessandra C, Roberto C, Antonello F, Alberto FM, Andrea F, Catherine B, Miles AK, Fabio TFM (2020) Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats. Insights Imaging 11:1\u201310","journal-title":"Insights Imaging"},{"key":"3189_CR202","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1365-2133.2008.08506.x","volume":"158","author":"M Singh","year":"2008","unstructured":"Singh M, Davenport A, Clatworthy I, Lewin J, Deroide F, Hubbard V et al (2008) A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger? Br J Dermatol 158:1358\u20131362. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08506.x","journal-title":"Br J Dermatol"},{"key":"3189_CR203","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2016160905","author":"APL Smith","year":"2017","unstructured":"Smith APL, Marino M, Roberts J, Crowder JM, Castle J, Lowery L et al (2017) Clearance of gadolinium from the brain with no pathologic effect after repeated administration of gadodiamide in healthy rats: an analytical and histologic study. Radiology. https:\/\/doi.org\/10.1148\/radiol.2016160905","journal-title":"Radiology"},{"key":"3189_CR204","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2214\/AJR.17.18655","volume":"210","author":"F Sodagari","year":"2018","unstructured":"Sodagari F, Mozaffary A, Wood CG, Schmitz B, Miller FH, Yaghmai V (2018) Reactions to both nonionic iodinated and gadolinium-based contrast media: incidence and clinical characteristics. Am J Roentgenol 210:715\u2013719. https:\/\/doi.org\/10.2214\/AJR.17.18655","journal-title":"Am J Roentgenol"},{"key":"3189_CR205","first-page":"289","volume":"32","author":"A Spinazzi","year":"2003","unstructured":"Spinazzi A, Lorusso V, Pirovano G, Kirchin M (2003) Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Appl Radiol 32:289\u2013291","journal-title":"Appl Radiol"},{"key":"3189_CR206","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11547-017-0816-9","volume":"123","author":"A Splendiani","year":"2018","unstructured":"Splendiani A, Perri M, Marsecano C, Vellucci V, Michelini G, Barile A et al (2018) Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. Radiol Medica 123:125\u2013134. https:\/\/doi.org\/10.1007\/s11547-017-0816-9","journal-title":"Radiol Medica"},{"key":"3189_CR207","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/00004424-199407000-00008","volume":"29","author":"T Staks","year":"1994","unstructured":"Staks T, Schuhmann-Giampier G, Frenzel T, Weinmann HJ, Lange L, Platzek J (1994) Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 29:709\u2013715. https:\/\/doi.org\/10.1097\/00004424-199407000-00008","journal-title":"Invest Radiol"},{"key":"3189_CR208","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00330-015-3879-9","volume":"26","author":"DA Stojanov","year":"2016","unstructured":"Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S (2016) Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 26:807\u2013815. https:\/\/doi.org\/10.1007\/s00330-015-3879-9","journal-title":"Eur Radiol"},{"key":"3189_CR209","first-page":"249","volume":"92","author":"SE Strickler","year":"2021","unstructured":"Strickler SE, Clark KR (2021) Gadolinium deposition: a study review. Radiol Technol 92:249\u2013258","journal-title":"Radiol Technol"},{"issue":"9","key":"3189_CR210","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/RLI.0000000000000774","volume":"56","author":"I Strzeminska","year":"2021","unstructured":"Strzeminska I, Robert P, Szpunar J, Corot C, Lobinkski R (2021) Speciation analysis of gadolinium in the water-insoluble rat brain fraction after administration of gadolinium-based contrast agents. Invest Radiol 56(9):535\u2013544. https:\/\/doi.org\/10.1097\/RLI.0000000000000774","journal-title":"Invest Radiol"},{"key":"3189_CR211","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0002-9343(03)00085-8","volume":"114","author":"RD Swartz","year":"2003","unstructured":"Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD (2003) Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114:563\u2013577. https:\/\/doi.org\/10.1016\/S0002-9343(03)00085-8","journal-title":"Am J Med"},{"key":"3189_CR212","volume-title":"Basic neurochemistry: molecular, cellular and medical aspects","author":"P Taylor","year":"1943","unstructured":"Taylor P, Brown JH (1943) Basic neurochemistry: molecular, cellular and medical aspects, 6th edn. Lippincott-Raven Publishers, Philadelphia","edition":"6"},{"key":"3189_CR213","first-page":"122","volume":"2017","author":"E Tedeschi","year":"2017","unstructured":"Tedeschi E, Caranci F, Giordano F, Angelini V, Cocozza S, Brunetti A (2017) Gadolinium retention in the body: what we know and what we can do. Radiol Medica 2017:122","journal-title":"Radiol Medica"},{"key":"3189_CR214","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/jmicro\/dfm020","volume":"56","author":"C Thakral","year":"2007","unstructured":"Thakral C, Abraham JL (2007) Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of Gadolinium deposits in skin. J Electron Microsc (tokyo) 56:181\u2013187. https:\/\/doi.org\/10.1093\/jmicro\/dfm020","journal-title":"J Electron Microsc (tokyo)"},{"key":"3189_CR215","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/j.1600-0560.2009.01283.x","volume":"36","author":"C Thakral","year":"2009","unstructured":"Thakral C, Abraham JL (2009) Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues. In vivo transmetallation confirmed by microanalysis. J Cutan Pathol 36:1244\u20131254. https:\/\/doi.org\/10.1111\/j.1600-0560.2009.01283.x","journal-title":"J Cutan Pathol"},{"key":"3189_CR216","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00330-012-2597-9","volume":"23","author":"HS Thomsen","year":"2013","unstructured":"Thomsen HS, Morcos SK, Alm\u00e9n T, Bellin MF, Bertolotto M, Bongartz G et al (2013) Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 23:307\u2013318. https:\/\/doi.org\/10.1007\/s00330-012-2597-9","journal-title":"Eur Radiol"},{"key":"3189_CR217","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/jmri.24664","volume":"41","author":"LK Thomson","year":"2015","unstructured":"Thomson LK, Thomson PC, Kingsmore DB, Blessing K, Daly CD, Cowper SE et al (2015) Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era. J Magn Reson Imaging 41:1268\u20131271. https:\/\/doi.org\/10.1002\/jmri.24664","journal-title":"J Magn Reson Imaging"},{"key":"3189_CR218","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1148\/radiol.2017161151","volume":"285","author":"D Tibussek","year":"2017","unstructured":"Tibussek D, Rademacher C, Caspers J, Turowski B, Schaper J, Antoch G et al (2017) Gadolinium brain deposition after macrocyclic gadolinium administration: a pediatric case-control study. Radiology 285:223\u2013230. https:\/\/doi.org\/10.1148\/radiol.2017161151","journal-title":"Radiology"},{"key":"3189_CR219","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1259\/bjr\/17689538","volume":"83","author":"Y Tsushima","year":"2010","unstructured":"Tsushima Y, Kanal E, Thomsen HS (2010) Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Br J Radiol 83:590\u2013595. https:\/\/doi.org\/10.1259\/bjr\/17689538","journal-title":"Br J Radiol"},{"key":"3189_CR220","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021210957","author":"MF Tweedle","year":"2021","unstructured":"Tweedle MF (2021) Gadolinium retention in human brain, bone, and skin. Radiology. https:\/\/doi.org\/10.1148\/radiol.2021210957","journal-title":"Radiology"},{"key":"3189_CR221","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/00004424-199506000-00008","volume":"30","author":"MF Tweedle","year":"1995","unstructured":"Tweedle MF, Wedeking P, Kumar K (1995) Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 30:372\u2013380. https:\/\/doi.org\/10.1097\/00004424-199506000-00008","journal-title":"Invest Radiol"},{"key":"3189_CR222","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/RLI.0b013e31818f76b5","volume":"44","author":"J Varani","year":"2009","unstructured":"Varani J, Dasilva M, Warner RL, Deming M\u00d3, Barron AG, Johnson KJ, Swartz RD (2009) Effects of gadolinium\u2014based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 44:74\u201381. https:\/\/doi.org\/10.1097\/RLI.0b013e31818f76b5","journal-title":"Invest Radiol"},{"key":"3189_CR223","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0720-048X(95)00679-K","volume":"21","author":"H Vogler","year":"1995","unstructured":"Vogler H, Platzek J, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Rad\u00fcchel B et al (1995) Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 21:1\u201310. https:\/\/doi.org\/10.1016\/0720-048X(95)00679-K","journal-title":"Eur J Radiol"},{"key":"3189_CR224","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/RLI.0b013e318263f128","volume":"47","author":"C Wack","year":"2012","unstructured":"Wack C, Steger-Hartmann T, Mylecraine L, Hofmeister R (2012) Toxicological safety evaluation of gadobutrol. Invest Radiol 47:611\u2013623. https:\/\/doi.org\/10.1097\/RLI.0b013e318263f128","journal-title":"Invest Radiol"},{"key":"3189_CR225","first-page":"119","volume":"2019","author":"J Wahsner","year":"2019","unstructured":"Wahsner J, Gale EM, Rodr\u00edguez-Rodr\u00edguez A, Caravan P (2019) Chemistry of MRI contrast agents: current challenges and new frontiers. Chem Rev 2019:119","journal-title":"Chem Rev"},{"key":"3189_CR226","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3978\/j.issn.2223-4292.2015.05.03","volume":"5","author":"Y-XJ W\u00e1ng","year":"2015","unstructured":"W\u00e1ng Y-XJ, Schroeder J, Siegmund H, Id\u00e9e J-M, Fretellier N, Jestin-Mayer G et al (2015) Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats. Quant Imaging Med Surg 5:534. https:\/\/doi.org\/10.3978\/j.issn.2223-4292.2015.05.03","journal-title":"Quant Imaging Med Surg"},{"key":"3189_CR227","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/rli.0000000000000571","volume":"54","author":"S Wang","year":"2019","unstructured":"Wang S, Hesse B, Roman M, Stier D, Castillo-Michel H, Cotte M et al (2019) Increased retention of gadolinium in the inflamed brain after repeated administration of gadopentetate dimeglumine. Invest Radiol 54:617\u2013626. https:\/\/doi.org\/10.1097\/rli.0000000000000571","journal-title":"Invest Radiol"},{"key":"3189_CR228","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00256-008-0464-1","volume":"37","author":"JP Weigle","year":"2008","unstructured":"Weigle JP, Broome DR (2008) Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. Skeletal Radiol 37:457\u2013446. https:\/\/doi.org\/10.1007\/s00256-008-0464-1","journal-title":"Skeletal Radiol"},{"key":"3189_CR229","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2214\/ajr.142.3.619","volume":"142","author":"HJ Weinmann","year":"1984","unstructured":"Weinmann HJ, Brasch RC, Press WR, Wesbey GE (1984) Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 142:619\u2013624. https:\/\/doi.org\/10.2214\/ajr.142.3.619","journal-title":"Am J Roentgenol"},{"key":"3189_CR230","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/mrm.1910220214","volume":"22","author":"H-J Weinmann","year":"1991","unstructured":"Weinmann H-J, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H (1991) A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 22:233\u2013237. https:\/\/doi.org\/10.1002\/mrm.1910220214","journal-title":"Magn Reson Med"},{"key":"3189_CR231","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/art.24471","volume":"60","author":"PJ Wermuth","year":"2009","unstructured":"Wermuth PJ, Del Galdo F, Jim\u00e9nez SA (2009) Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 60:1508\u20131518. https:\/\/doi.org\/10.1002\/art.24471","journal-title":"Arthritis Rheum"},{"key":"3189_CR232","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/01.rli.0000186569.32408.95","volume":"41","author":"GW White","year":"2006","unstructured":"White GW, Gibby WA, Tweedle MF (2006) Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41:272\u2013278. https:\/\/doi.org\/10.1097\/01.rli.0000186569.32408.95","journal-title":"Invest Radiol"},{"key":"3189_CR233","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","volume":"180","author":"SA Woolen","year":"2020","unstructured":"Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS (2020) Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med 180:223\u2013230. https:\/\/doi.org\/10.1001\/jamainternmed.2019.5284","journal-title":"JAMA Intern Med"},{"key":"3189_CR234","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3109\/02841851.2010.515614","volume":"51","author":"D Xia","year":"2010","unstructured":"Xia D, Davis RL, Crawford JA, Abraham JL (2010) Gadolinium released from MR contrast agents is deposited in brain tumors: In situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Acta Radiol 51:1126\u20131136. https:\/\/doi.org\/10.3109\/02841851.2010.515614","journal-title":"Acta Radiol"},{"key":"3189_CR235","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1021\/bi00403a033","volume":"27","author":"O Zak","year":"1988","unstructured":"Zak O, Aisen P (1988) Spectroscopic and thermodynamic studies on the binding of gadolinium(III) to human serum transferrin. Biochemistry 27:1075\u20131080. https:\/\/doi.org\/10.1021\/bi00403a033","journal-title":"Biochemistry"},{"key":"3189_CR236","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","volume":"12","author":"BV Zlokovic","year":"2011","unstructured":"Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat Rev Neurosci 12:723\u2013738","journal-title":"Nat Rev Neurosci"},{"key":"3189_CR237","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.jcmg.2011.08.013","volume":"4","author":"Z Zou","year":"2011","unstructured":"Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR (2011) Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 4:1206\u20131216","journal-title":"JACC Cardiovasc Imaging"}],"updated-by":[{"DOI":"10.1007\/s00204-022-03243-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000}}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-021-03189-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-021-03189-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-021-03189-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T22:31:53Z","timestamp":1676068313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-021-03189-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":235,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3189"],"URL":"https:\/\/doi.org\/10.1007\/s00204-021-03189-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00204-022-03243-z","asserted-by":"object"}]},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"11 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00204-022-03243-z","URL":"https:\/\/doi.org\/10.1007\/s00204-022-03243-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors were employees of GE Healthcare at the time of writing and submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}